EFFICACY AND SAFETY OF VILDAGLIPTIN AS ADD-ON THERAPY TO PIOGLITAZONE IN PATIENTS WITH TYPE II DIABETES MELLITUS

Abstract

Background: Diabetes mellitus type II (DM) is a chronic metabolic condition characterized by insulin resistance and decreased insulin production. In patients with type II diabetes, the combination of pioglitazone and vildagliptin has been demonstrated to enhance glycemic control. However, studies investigating the effectiveness and safety of this combination treatment in the real-world setting are insufficient.

Objectives: this retrospective study was to assess the effectiveness and safety of vildagliptin when used as supplementary treatment with pioglitazone for patients diagnosed with type II diabetes mellitus

Study design:  A Retrospective Study

Duration and place of study: department of medicine mmc mardan from jan 2022 to jan 2023

Methods: The study comprised 65 patients who received a combination therapy of vildagliptin/pioglitazone at either a high dosage of 100/30 mg once daily (n=35) or a low dose of 50/15 mg once daily (n=30). Additionally, some patients received monotherapy with either vildagliptin at 100 mg once daily (n=33) or pioglitazone at 30 mg once daily (n=32). The secondary objectives included changes in fasting plasma glucose (FPG) concentrations, body weight, and any adverse events.

Results:

The study included 65 patients, 56.9% males and 43.07% females. The average age of the participants was 58.5 years, ranging from 16 to 75 years. 11 common adverse events were observed, the most common of which was nasopharyngitis (4.6%). Dizziness, headache, upper respiratory tract infection, asthenia, and constipation were all typical side effects. Vildagliptin/Pioglitazone 100/30 mg once daily (n=35), 50/15 mg (n=30), 100 mg Vildagliptin (n=33), and 30 mg Pioglitazone (n=32) were used in the study. For glycemic control, baseline HbA1c levels ranged from 8.2% in the Vildagliptin/Pioglitazone 100/30 mg group to 8.9% in the 30 mg group. At baseline, fasting plasma glucose (FPG) levels varied from 9.2 mmol/L in the Vildagliptin/Pioglitazone 100/30 mg group to 10.3 mmol/L in the 50/15 mg group. T2DM lasted 3.5-4.2 years in all participants.

Conclusion: Incorporating vildagliptin into pioglitazone treatment among patients diagnosed with type II diabetes mellitus led to notable enhancements in glycemic regulation while exhibiting no substantial alterations in body weight. The combination therapy demonstrated favorable tolerability and may be considered a viable and secure therapeutic approach for those diagnosed with type II diabetes mellitus.